Norwegian biotech company Arctic Bioscience (Euronext Growth Oslo:ABS) has entered into an agreement for a new clinical study on psoriasis with its drug candidate HRO350, which is developed from herring roe oil, the company announced on Wednesday.
The three-year agreement with Smerud Medical Research International is worth NOK75m.
The phase IIb study aims to investigate the efficacy and safety of HRO350 and to establish the optimal dose.
More than 500 patients with mild to moderate psoriasis will be recruited in seven countries, including Norway, starting in the first quarter of 2022.
Arctic Bioscience recently raised NOK300m and was listed on the Euronext Growth market in Oslo on 24 February 2021.
(EUR1=NOK10.21)
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study